MedPath

ate phase II study of NS-304 in patients with intermittent claudication (IC) resulting from arteriosclerosis obliterans (ASO)

Phase 2
Completed
Conditions
Arteriosclerosis obliterans (ASO)
Registration Number
JPRN-jRCT2080223273
Lead Sponsor
ippon Shinyaku Co., Ltd.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
completed
Sex
All
Target Recruitment
342
Inclusion Criteria

Patients with intermittent claudication (IC) resulting from arteriosclerosis obliterans (ASO)

Exclusion Criteria

Patients who have severe ischemia of lower extremities of Stage III or over in Fontaine classification or potentially has severe ischemia of lower extremities

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
efficacy<br>Natural log transformed peak walking time (ln PWT)
Secondary Outcome Measures
NameTimeMethod
efficacy<br>Natural log transformed claudication onset time (ln COT)
© Copyright 2025. All Rights Reserved by MedPath